Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Tesaro Inc.
Sponsor

Tesaro Inc.

United States 1000 Winter Street Suite 3300, 02451-1230, United States

About the sponsor

Clinical research is centered on advanced ovarian cancer, including stage III and stage IV disease, with attention to non-mucinous epithelial ovarian cancer and fallopian and peritoneal cancers. The studies also focus on tumors with HRD features and treatment after response to platinum-based chemotherapy.

  • Maintenance therapy
  • Neoadjuvant treatment
  • HRD-positive ovarian cancer
  • Platinum-sensitive disease

The portfolio includes work in both newly treated and recurrent settings, with emphasis on disease control in advanced ovarian malignancies.

About Specializations

Tesaro Inc. runs clinical trials in conditions such as Ovarian cancer, Homologous recombination deficiency positive advanced ovarian cancer, Ovarian cancer stage IV, Ovarian cancer stage III, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Ovarian cancer+1

Not recruiting

Study Comparing Niraparib and Platinum-Taxane Drug Combination for Patients with Advanced Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Tesaro Inc.

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Ovarian cancer

Not recruiting

Study on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Tesaro Inc.

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.